Biotech & Genomic Medicine▲
Huayang Intelligent 2026 Interim Report: Drug Delivery Devices Surge, Earnings Steady and Cash Flow Improves
Huayang Intelligent released its 2026 interim report on August 26. Driven by its dual engines of micro motors and precision drug delivery devices, the company achieved steady earnings growth during the reporting period, with a significant improvement in operating cash flow. Financial data show that the company recorded operating revenue of 251 million yuan, up 6.74 percent year on year; net profit attributable to the parent company of 18 million yuan, up 3.74 percent; non-GAAP net profit of 16 million yuan, up 14.62 percent; and net cash flow from operating activities of 50 million yuan, a sharp year-on-year increase of 221.10 percent, turning from a net outflow to a net inflow. In terms of business structure, revenue from micro motors and components fell 1.91 percent year on year to 214 million yuan, accounting for about 85 percent of total revenue; revenue from the precision drug delivery device business surged 126.29 percent year on year to 34 million yuan, becoming a second growth curve. The company seized opportunities from the expanding market for GLP-1 drugs and growth hormone, with rapid order fulfillment for injection pens and other products, offsetting pressure from the decline in its traditional business. Looking ahead, precision drug delivery devices are expected to maintain strong momentum, but attention should be paid to risks such as raw material price fluctuations, weaker-than-expected recovery in home appliance demand, and longer approval cycles for medical devices.